Heidi J. Wehring, PharmD

Univeristy of Iowa, BS, Psychology, 1995

University of Iowa, PharmD, Pharmacy, 2000

University of Maryland, Psychiatric Pharmacy Residency, 2001

University of Maryland School of Medicine, Postdoctoral Psychiatry Fellowship, 2011

Dr. Wehring is an Assistant Professor of Psychiatry, Maryland Psychiatric Research Center.  Dr. Wehring is a board-certified psychiatric pharmacist and has dedicated her career to specializing in clinical research and treatment of adults and children with serious mental illness.  Her main areas of interest include treatment-resistant schizophrenia, co-occurring mental illness and substance use disorders, and psychopharmacology in pediatric populations.

Schizophrenia, Tobacco Craving, Smoking Cessation, Pediatric Psychopharmacology

Wehring HJ*, Elsobky T*, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon E, Kelly DL.  Adjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levels.  Psychiatric Quarterly, in press 2017.

Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, Weiner E, Kelly DL.  Antipsychotic treatment and tobacco craving in people with schizophrenia.  J Dual Diagn 2017 Feb; [Epub ahead of print]. PMID: 28166471.

Wehring HJ, Perez G, Dixon L, Kelly DL.  Women and Addiction:  Compounding the picture with mental illness.  Current Women’s Health Reviews, 2013.

Wehring HJ, Liu F, McMahon RP, Mackowick KM, Love RC, Dixon L, Kelly DL. Clinical Characteristics of Heavy and Light Smokers with Schizophrenia. Schizophrenia Research; 138(2-3):285-9. PMID: 22578720